Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) has renewed two agreements to continue leasing certain property and assets from controlling shareholder Kelun Pharmaceutical for the three years ending Dec. 31, 2027, a Jan. 28 bourse filing said.
The leased properties in Chengdu, China, are being used by the company for its daily operations, such as for R&D activities, and as a storage house, office space, and staff housing solution.
The equipment comprises around 1,074 pieces of equipment including manufacturing and laboratory equipment and instruments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments